DXCM vs ISRG vs MCK Stock Comparison

Dexcom, Intuitive Surgical and Mckesson Prices as of Nov 13, 2026 Peers: Industry group
DXCM Dexcom Inc
$83.33 -0.2% 1M +39.5% 1Y
Market cap
$30.72B
P/E
31.0x
Revenue (TTM)
$5.10B
Div. yield
–
Medical Devices Healthcare
2 wins
ISRG Intuitive Surgical Inc
$443.59 +5.6% 1M -21.6% 1Y
Market cap
$152.73B
P/E
51.6x
Revenue (TTM)
$11.58B
Div. yield
–
Medical Devices Healthcare
4 wins
MCK Mckesson Corp
$1,102.82 +12.7% 1M +30.3% 1Y
Market cap
$128.78B
P/E
27.4x
Revenue (TTM)
$418.79B
Div. yield
0.00%
Drug Distribution Healthcare
5 wins

Head to Head

11 decided of 12

Mckesson leads on 5 of the 12 questions below (Mckesson 5, Intuitive Surgical 4, Dexcom 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionDXCMISRGMCKLeader
Larger companyMarket capitalisation $30.72B $152.73B $128.78B ISRG
Cheaper on earningsLower P/E, profitable companies only 31.0x 51.6x 27.4x MCK
Cheaper on forward earningsLower price / next fiscal year consensus EPS 29.1x 38.5x 22.8x MCK
Faster revenue growthRevenue growth, trailing twelve months +13.0% +20.5% +8.2% ISRG
More profitableNet margin, trailing twelve months 19.4% 25.5% 1.1% ISRG
Better return on capitalReturn on invested capital 32.4% — 98.7% MCK
Less leveragedLower net debt / EBITDA -0.9x — 0.4x DXCM
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +39.5% -21.6% +30.3% DXCM
Better 5-year returnAnnualised price return, 5 years -12.4%/yr +4.6%/yr +37.5%/yr MCK
Less volatileAnnualised volatility, 1 year 37.9% 36.1% 31.4% MCK
Higher overall scoreMean of the five percentile scores vs peers 80/100 81/100 58/100 ISRG

Percentile Scorecard

DXCMISRGMCK

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisDXCMISRGMCK
Valuation 67 #82 of 243 52 #118 of 243 65 #10 of 27
Growth 83 #40 of 228 81 #45 of 228 56 #12 of 26
Profitability 100 #1 of 222 97 #7 of 222 56 #12 of 26
Financial Health 59 #103 of 248 81 #47 of 248 56 #12 of 26
Shareholder Returns 91 #15 of 158 95 #9 of 158 59 #8 of 18
Overall 80 81 58
  • DXCM ranked among 252 companies in Medical Devices and Diagnostics
  • ISRG ranked among 252 companies in Medical Devices and Diagnostics
  • MCK ranked among 27 companies in Healthcare Payers and Distributors

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodDXCMISRGMCKSPY
1 month -0.2%+5.6%+12.7% -2.0%
3 months -7.2%+12.4%+26.9% -2.8%
6 months +35.2%+5.3%+45.0% +2.0%
Year to date +25.6%-21.7%+34.4% +10.6%
1 year +39.5%-21.6%+30.3% +12.2%
3 years -17.8%+52.1%+143.0% +68.1%
3 years, per year -6.3%+15.0%+34.5% +18.9%
5 years -48.4%+25.0%+390.5% +61.4%
5 years, per year -12.4%+4.6%+37.5% +10.1%
10 years +411.2%+542.1%+671.0% +248.5%
10 years, per year +17.7%+20.4%+22.7% +13.3%

Risk

MeasureDXCMISRGMCKSPY
Volatility, 1Y 37.9%36.1%31.4% 13.6%
Downside volatility, 1Y 34.3%38.4%27.2% 13.9%
Beta vs S&P 500, 1Y 0.720.92-0.18 1.00
Return / volatility, 1Y 1.04-0.600.97 0.90
Max drawdown, 5Y -66.3%-49.9%-27.2% -25.4%
From 52-week high -9.8%-25.2%0.0% -3.2%
52-week high $92.34$592.85$1,102.82 $779.14
52-week low $57.56$332.02$725.17 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleDXCMISRGMCK
P/E now vs peer median 31.5xmedian 26.5x 52.4xmedian 26.5x 27.3xmedian 25.2x
P/S now vs peer median 6.1xmedian 2.7x 13.3xmedian 2.7x 0.3xmedian 0.4x
EV/EBITDA now vs peer median 19.7xmedian 18.4x 36.6xmedian 18.4x 17.4xmedian 14.5x
P/FCF now vs peer median 28.3xmedian 25.4x 42.7xmedian 25.4x 17.9xmedian 16.5x
P/B now vs peer median 12.3xmedian 2.5x 9.5xmedian 2.5x -32.2xmedian 2.7x
PEG now vs peer median 0.73median 0.98 2.04median 0.98 1.72median 1.72

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsDXCMISRGMCK
Revenue $5.10B $11.58B $418.79B
Gross profit $3.24B $7.78B $15.37B
Operating income $1.22B $3.28B $6.69B
Net income $991.00M $2.97B $5.43B
Free cash flow $1.10B $3.60B $7.11B
R&D $608.10M $1.49B –
EPS (diluted) $2.58 $8.41 $40.27
Cash & equivalents $961.40M $2.98B $6.53B
Total debt $389.80M – $9.21B
Shares (diluted) 383.50M 351.60M 116.70M
Enterprise value $22.54B $133.02B $110.16B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricDXCMISRGMCK
P/E 31.5x 52.4x 27.3x
P/FCF 28.3x 42.7x 17.9x
P/Operating cash flow 22.0x 37.6x 17.0x
P/S 6.1x 13.3x 0.3x
P/B 12.3x 9.5x -32.2x
P/Tangible book 12.7x 10.3x -16.1x
EV/EBITDA 19.7x 36.6x 17.4x
EV/EBIT 24.2x 45.6x 19.4x
EV/Revenue 5.8x 12.9x 0.3x
EV/FCF 27.0x 41.6x 18.3x
EV/Operating cash flow 21.0x 36.6x 17.3x
PEG (3Y EPS CAGR) 0.73 2.04 1.72

Growth

14 metrics
MetricDXCMISRGMCK
Revenue growth (1Y) 13.0% 20.5% 8.2%
Revenue CAGR (3Y) 14.5% 19.1% 12.9%
Gross profit growth (1Y) 21.5% 21.9% 11.8%
Gross profit CAGR (3Y) 14.2% 19.5% 7.6%
Operating income growth (1Y) 57.4% 16.6% 27.3%
Operating income CAGR (3Y) 34.2% 24.8% 16.1%
Net income growth (1Y) 37.5% 7.5% 28.5%
Net income CAGR (3Y) 38.0% 24.4% 14.2%
EPS growth (1Y) 46.1% 10.8% 24.2%
EPS CAGR (3Y) 43.0% 25.7% 15.9%
Operating cash flow growth (1Y) -2.3% 38.1% 9.3%
Operating cash flow CAGR (3Y) 23.7% 26.4% 15.2%
Free cash flow growth (1Y) 3.4% 58.4% 11.8%
Free cash flow CAGR (3Y) 30.0% 42.0% 16.3%

Profitability

14 metrics
MetricDXCMISRGMCK
Gross margin 63.4% 67.2% 3.7%
EBITDA margin 29.5% 35.3% 1.8%
Operating margin 24.0% 28.4% 1.6%
Pretax margin 24.7% 31.3% 1.6%
Net margin 19.4% 25.5% 1.1%
FCF margin 21.5% 31.1% 1.7%
Operating cash flow margin 27.7% 35.3% 1.8%
Return on equity 38.4% 17.3% –
Return on assets 15.6% 14.8% 6.0%
Return on invested capital 32.4% – 98.7%
Return on capital employed 29.9% 18.7% 42.0%
Asset turnover 0.8x 0.6x 4.6x
Cash conversion (OCF / net income) 1.4x 1.4x 1.4x
Stock comp / revenue 3.0% 7.2% –

Financial Health

11 metrics
MetricDXCMISRGMCK
Debt / assets 6.2% – 10.0%
Debt / equity 0.2x – -2.3x
Net debt / EBITDA -0.9x – 0.4x
Debt / FCF 0.4x – 1.3x
Liabilities / assets 59.4% 16.7% 104.3%
Equity / assets 40.6% 83.3% -4.3%
Interest coverage – – 21.9x
Current ratio 1.7x 3.3x 0.9x
Quick ratio 1.3x 2.3x 0.5x
Cash ratio 0.8x 1.6x 0.1x
Altman Z-score 7.53 30.40 5.83

Shareholder Returns

7 metrics
MetricDXCMISRGMCK
Dividend yield – – 0.3%
Net buyback yield 2.2% 2.8% 5.2%
Shareholder yield 2.2% 2.8% 5.6%
Payout ratio (earnings) – – 7.4%
Payout ratio (FCF) – – 5.6%
Dividend growth (1Y) – – 10.5%
Dividend CAGR (3Y) – – 9.8%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusDXCMISRGMCK
Forward P/E 29.1xFY2026 38.5xFY2026 22.8xFY2026
EPS, next fiscal year $2.86FY2026 $11.52FY2026 $48.34FY2026
EPS growth, next FY +36.8%FY2026 +29.0%FY2026 +23.6%FY2026
EPS growth, the year after +4.2% +4.5% +11.9%
Revenue, next fiscal year $5.08BFY2026 $11.62BFY2026 $447.65BFY2026
Revenue growth, next FY +9.0%FY2026 +15.5%FY2026 +11.0%FY2026
Revenue growth, the year after +16.0% +11.3% +1.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersDXCMISRGMCK
Held by institutions 100.0% 86.2% 89.1%
Institutions holding 977 2,241 2,014
Change in shares held, QoQ +6.3% +4.6% -0.7%
Institutions buying 521 1,073 883
Institutions selling 345 879 793
Buyers to sellers 1.51 1.22 1.11

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

DXCMISRGMCK
DXCM 1.00 0.43 0.15
ISRG 0.43 1.00 0.16
MCK 0.15 0.16 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, DXCM, ISRG and MCK?

Intuitive Surgical (ISRG) is the largest by market capitalisation: Dexcom (DXCM) $30.72B, Intuitive Surgical (ISRG) $152.73B, Mckesson (MCK) $128.78B.

Which stock is cheaper, DXCM, ISRG and MCK?

Mckesson (MCK) trades on the lowest price-to-earnings ratio (Dexcom (DXCM) 31.0x, Intuitive Surgical (ISRG) 51.6x, Mckesson (MCK) 27.4x). On next year's consensus earnings, Mckesson (MCK) is cheapest (Dexcom (DXCM) 29.1x, Intuitive Surgical (ISRG) 38.5x, Mckesson (MCK) 22.8x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Intuitive Surgical (ISRG) grew revenue fastest over the trailing twelve months: Dexcom (DXCM) +13.0%, Intuitive Surgical (ISRG) +20.5%, Mckesson (MCK) +8.2%.

Which company is more profitable?

Intuitive Surgical (ISRG) has the highest net margin (Dexcom (DXCM) 19.4%, Intuitive Surgical (ISRG) 25.5%, Mckesson (MCK) 1.1%). On return on invested capital, Mckesson (MCK) leads (Dexcom (DXCM) 32.4%, Mckesson (MCK) 98.7%).

Which stock has performed better?

Over the past year Dexcom (DXCM) returned the most: Dexcom (DXCM) +39.5%, Intuitive Surgical (ISRG) -21.6%, Mckesson (MCK) +30.3%. Over five years, Mckesson (MCK) compounded fastest (Dexcom (DXCM) -12.4%/yr, Intuitive Surgical (ISRG) +4.6%/yr, Mckesson (MCK) +37.5%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Dexcom (DXCM) 0.00%, Intuitive Surgical (ISRG) 0.00%, Mckesson (MCK) 0.00%. Dexcom (DXCM) and Intuitive Surgical (ISRG) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Mckesson (MCK) has been the steadiest (Dexcom (DXCM) 37.9%, Intuitive Surgical (ISRG) 36.1%, Mckesson (MCK) 31.4%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, DXCM, ISRG and MCK?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Mckesson (MCK) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.